IGC Pharma Reports First Quarter Results; Company Continues to Make Significant Progress Advancing Its Lead Alzheimer’s Candidate Through Phase 2 Clinical Trials August 14, 2023
IGC Pharma, Inc. Presenting 6 Posters on the Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms in Dementia at the 2023 Alzheimer’s Association International Conference July 18, 2023
IGC Pharma Secures $12 Million Line of Credit from O-Bank Strengthening Efforts in Alzheimer’s Research July 7, 2023
